News
-
-
PRESS RELEASE
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
Mainz Biomed to showcase ColoAlert® at Gynecology Conference in Stuttgart, Germany, highlighting the importance of early CRC detection and gynecologists' role in screenings -
-
PRESS RELEASE
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
Mainz Biomed partners with Praxisdienst to distribute ColoAlert®, an innovative at-home stool test for colorectal cancer detection. The collaboration aims to improve healthcare by enhancing early diagnosis -
-
PRESS RELEASE
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Mainz Biomed partners with TomaLab to expand ColoAlert® availability in Italy, enhancing colorectal cancer screening. Collaboration brings advanced DNA technology for early detection to Italian healthcare -
PRESS RELEASE
MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
Mainz Biomed N.V. (NASDAQ:MYNZ) has established the 'European Oncology Lab' (EOL), a physician-led laboratory for expanding service offering to privately insured patients in Germany. The lab will offer ColoAlert® as a laboratory medical service directly to physicians and patients, addressing the crucial requirement for invoicing private health insurance companies -
-
-
